The company’s clinical programs include VK2809, a novel, orally available, small molecule selective thyroid ... Additionally, Syfovre and Empaveli came short of expectations, with Syfovre ...

The firm thinks Q3 was validating for its view of a slowing GA market and that Syfovre estimates need to be reset. Wells believes incrementally negative commentary on pricing and more gradual ramp ...

The company missed on both the topline and bottom line, the analyst tells investors. Additionally, Syfovre and Empaveli came short of expectations, with Syfovre’s launch facing headwinds due to ...

The US regulator has cleared the company’s complement C3 inhibitor pegcetacoplan as an intravitreal injection called Syfovre for GA, which affects more than 5 million people worldwide ...

EyePoint Pharmaceuticals (EYPT) came out with a quarterly loss of $0.54 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.33 per share a year ago.

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Apellis Pharmaceuticals in a research note ...

and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email ...

Apellis’ application to market its complement C3 inhibitor Syfovre (pegcetacoplan) to treat geographic atrophy (GA) – a sight-robbing condition that accompanies age-related macular ...

There is a great need for more effective treatments for geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to reduce individual and societal burdens.Clinicians currently have ...